Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia

Research output: Contribution to journal › Article › peer-review

224 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences